InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,482.87
(
0.09%
)
US TECH 100
19,239.20
(
0.13%
)
Dow Jones
39,164.06
(
0.09%
)
Brent Oil
85.30
(
0.98%
)
Bitcoin
61,402.70
(
0.97%
)
Post# of 1645
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

midastouch017

Send PM Follow Ignore
Followers 144
Posts 27604
Boards Moderated 3
Alias Born 02/07/2004

midastouch017

Re: gfp927z post# 1335

Tuesday, 10/06/2020 12:45:08 PM

Tuesday, October 06, 2020 12:45:08 PM

Post# of 1645
Gamida Cell Announces Positive Topline Data on Secondary Endpoints from Phase 3 Clinical Study of Omidubicel in Patients with Hematologic Malignancies
Business Wire Business Wire•October 6, 2020
— Study met secondary endpoints related to platelet engraftment, infections and hospitalizations, key clinical measures in bone marrow transplant —

— Omidubicel represents potential transformative treatment option for patients in need of a bone marrow transplant —

— Company anticipates initiating BLA submission in fourth quarter of 2020 —

https://finance.yahoo.com/news/gamida-cell-announces-positive-topline-103100746.html
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up